AV

Armen Vidian

Venture Capitalist

📍 San Francisco, California, United States🔄 Updated September 2026💼 9 investments📅 10 years investing🗓 Last invested Jan 2022𝕏 @upgrade_to_unlock
VC🌍 United States
9
Total investments
1
Early stage
6
Mid stage
0
Late stage
10y
Years active

Portfolio

7 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer
Jan 2022
Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs. The company was founded in 2019 to deliver on the promise of AI-Drug discovery. With more than 182 compounds for 26 targets, they are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA.
Board Member
Jun 2020
Proprio is a medical technology company based in Seattle, Washington. We create the new way of seeing™ in surgery through a proprietary platform of artificial intelligence, computer vision, and augmented/virtual reality. Our goal is to significantly improve patient outcomes and surgeon wellbeing through the collaboration of physician expertise and immersive, intelligent technology. We work closely with industry-leading medical and technical advisors and reputable research institutions specializing in neurosurgery, medical devices, AI, computer vision, and robotics to dimensionalize and digitize surgical vision in groundbreaking, real-time applications. A quickly-growing, award-winning company, our team consists of creative, diverse, multi-disciplinary thinkers and innovators who value designing technology for positive and unprecedented social and industry impact.
Board Member
2019
Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery. Our mission is to create new knowledge driven by data, computation, automation, and high-throughput robotics with the goal of fundamentally advancing the life sciences. The Strateos Automation-as-a-Service Platform helps scientists more efficiently and reproducibly design, run, and analyze experiments to achieve new and faster scientific discoveries.
Board Member
2019
Cofactor Genomics’s mission is to create diagnostics that have the ability to predict the patients that can benefit from immunotherapies. Using more insightful multidimensional biomarkers created with RNA and machine learning, Cofactor’s diagnostics offer greater predictive power than any current test. Instead of searching for isolated, single-analyte biomarkers or DNA mutations, Cofactor’s products create multidimensional biomarkers that better capture the complex immune response at the site of a tumor. Cofactor Genomics empowers clinicians to be better informed while making treatment decisions to improve patient outcomes.
mid stageBiotechnology
Board Member
Jul 2017
Vium is the first company to create a living informatics platform for preclinical in vivo drug research. The Vium Digital Vivarium™, incorporating Vium Smart Housing™, Vium Cloud infrastructure, and online Research Suite software, empowers scientists to optimize advances in bioengineered research models in ways previously not possible. Vium is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the “3 Rs,” the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical and computational drug discovery companies to academia and novel therapeutic labs. Investors include Lux Capital, Data Collective, Dolby Family Ventures, AME Cloud Ventures, and Founders Fund. For more information, please visit www.vium.com.
Board Member
Nov 2016
Founded in 2012, Transcriptic has developed the first robotic cloud lab platform for on-demand life science research. It’s powered by the Transcriptic Common Lab Environment (TCLE) a scalable, digital infrastructure that integrates laboratory processes, instruments and IoT technologies into a single user interface. Researchers can carry out scalable, reproducible and rapid experimentation from anywhere in the world. Top ten pharmaceutical companies, as well as emerging biotech companies, are using the platform to gain more reproducibility and flexibility in the design and control of their experiments. By leveraging cloud-based technologies, users can access the power of a fully automated laboratory – whether in their own labs through an on-premise deployment of TCLE or through Transcriptic’s Bioassays services – all through a simple web-based interface. Transcriptic is transforming drug discovery and synthetic biology research by helping scientists focus on accelerating discoveries instead of labor-intensive bench work.
mid stageBiotechnology
Board Member
2016
Caption Health has developed the AI platform that enables heart ultrasound access for early disease detection—when there is the highest potential for impact. Our breakthrough Caption AI technology is the first FDA cleared AI-guided medical imaging acquisition software, enabling more healthcare professionals to capture diagnostic-quality ultrasound images in more care settings. Caption AI powers Caption Care, a turnkey echo program that offers health plans and value-based care organizations convenient and cost-effective echocardiograms for their members. Caption Health was acquired by GE HealthCare in 2023 and has been recognized as one of TIME’s “100 Best Inventions” and Fast Company’s “Next Big Things in Tech”. Interested in creating a world where healthcare has no limits? Check out open roles at jobs.gecareers.com/healthcare/.
Experience · 13 entries
All (13)
Investments (9)
Founder (1)
Board (9)
2022
Board Observer
Jan 2022
Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs. The company was founded in 2019 to deliver on the promise of AI-Drug discovery. With more than 182 compounds for 26 targets, they are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA.
Founder & Managing Partner
2022
Recode Ventures is worlds first specialist VC firm dedicated to investing in healthcare AI companies. Based in San Francisco and London, we back founders who with whom we share the belief that artificial intelligence and other emerging platforms have the potential to revolutionize healthcare, treating and curing diseases that impact billions of lives worldwide. Our portfolio, spanning the United States and Europe, showcases pioneering ventures at the vanguard of medical innovation. From gene targeting and antibody development to cell therapy, cardiology, and surgical guidance, these companies are not only advancing medical science but also reshaping the landscape of healthcare delivery Recode prefers to invest early and to back founders with strong technical backgrounds.
2020
Board Member
Jun 2020
Proprio is a medical technology company based in Seattle, Washington. We create the new way of seeing™ in surgery through a proprietary platform of artificial intelligence, computer vision, and augmented/virtual reality. Our goal is to significantly improve patient outcomes and surgeon wellbeing through the collaboration of physician expertise and immersive, intelligent technology. We work closely with industry-leading medical and technical advisors and reputable research institutions specializing in neurosurgery, medical devices, AI, computer vision, and robotics to dimensionalize and digitize surgical vision in groundbreaking, real-time applications. A quickly-growing, award-winning company, our team consists of creative, diverse, multi-disciplinary thinkers and innovators who value designing technology for positive and unprecedented social and industry impact.
2019
Strateos
Board Member
May 2019
Board Member
2019
Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery. Our mission is to create new knowledge driven by data, computation, automation, and high-throughput robotics with the goal of fundamentally advancing the life sciences. The Strateos Automation-as-a-Service Platform helps scientists more efficiently and reproducibly design, run, and analyze experiments to achieve new and faster scientific discoveries.
Show all 13 entries ↓
Investment activity
2016–2022 · 9 investments
2016320171201932020120221
Recent (last 2 years)Earlier